Moleculin Biotech (MBRX) – Research Analysts’ Weekly Ratings Changes

Moleculin Biotech (NASDAQ: MBRX) recently received a number of ratings updates from brokerages and research firms:

• 3/13/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/5/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/3/2025 – Moleculin Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
• 2/25/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/17/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/12/2025 – Moleculin Biotech was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating.
• 2/9/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/1/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/24/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/16/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Moleculin Biotech Price Performance

MBRX stock opened at $1.16 on Friday. The company’s 50-day moving average is $1.44 and its 200-day moving average is $2.08. Moleculin Biotech, Inc. has a 1 year low of $0.40 and a 1 year high of $8.85.

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.